Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling

Lu Wang,Liang Du,Xiao Xiong,Yusheng Lin,Jianlin Zhu,Zhimeng Yao,Shuhong Wang,Yi Guo,Yuping Chen,Kyla Geary,Yunlong Pan,Fuyou Zhou,Shegan Gao,Dianzheng Zhang,Sai-Ching Jim Yeung,Hao Zhang
DOI: https://doi.org/10.1038/s41388-021-01682-z
IF: 8.756
2021-02-18
Oncogene
Abstract:Abstract Smoking is one of the most impactful lifestyle-related risk factors in many cancer types including esophageal squamous cell carcinoma (ESCC). As the major component of tobacco and e-cigarettes, nicotine is not only responsible for addiction to smoking but also a carcinogen. Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the JAK2/STAT3 signaling pathway. We found that aberrant CHRNA7 expression can serve as an independent prognostic factor for ESCC patients. In multiple ESCC mouse models, dextromethorphan and metformin synergistically repressed nicotine-enhanced cancer-initiating cells (CIC) properties and inhibited ESCC progression. Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7 . Since dextromethorphan and metformin are two safe FDA-approved drugs with minimal undesirable side-effects, the combination of these drugs has a high potential as either a preventive and/or a therapeutic strategy against nicotine-promoted ESCC and perhaps other nicotine-sensitive cancer types as well.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The paper attempts to address the issue of how nicotine enhances the malignancy and tumor-initiating capacity of esophageal squamous cell carcinoma (ESCC) and explores methods to inhibit the JAK2/STAT3/SOX2 signaling pathway by directly targeting CHRNA7, thereby finding effective therapeutic strategies. Specifically, the main research objectives of the paper include: 1. **Revealing the mechanism of nicotine action**: - Investigate how nicotine, through interaction with CHRNA7, activates the JAK2/STAT3 signaling pathway, thereby enhancing the malignancy and tumor-initiating capacity of ESCC. - Explore the expression levels of CHRNA7 in ESCC and its relationship with patient prognosis. 2. **Finding effective therapeutic strategies**: - Evaluate whether two approved drugs—dextromethorphan and metformin—can synergistically inhibit nicotine-induced ESCC progression through different mechanisms. - Dextromethorphan inhibits CHRNA7 activity non-competitively, while metformin downregulates CHRNA7 expression by enhancing DNA hypermethylation of the CHRNA7 promoter. 3. **Validating the effectiveness of therapeutic strategies**: - In multiple ESCC mouse models, verify whether the combination of these two drugs can effectively inhibit the tumor-initiating cell (CIC) properties enhanced by nicotine, as well as the progression of ESCC. - Through in vitro and in vivo experiments, validate the impact of these drug combinations on the CHRNA7/JAK2/STAT3/SOX2 signaling pathway. In summary, the paper aims to propose a new and effective therapeutic strategy by revealing the molecular mechanisms of nicotine-induced ESCC deterioration, utilizing approved drug combinations to inhibit the carcinogenic effects of nicotine.